FiercePharma, by Eric Sagonowsky, Apr 10, 2019 For years, drugmakers and PBMs have tussled over who’s to blame for high drug prices. That didn’t change Tuesday when a congressional committee hauled in executives from insulin makers Sanofi, Eli Lilly and Novo Nordisk as well as from pharmacy benefit managers CVS, Express Scripts and Optum. Going […]
FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]
10. Aug. 2016, FiercePharma, Tracy Staton Copay discount programsbecome popular among biosimilar manufacturers to boost the adoption of their products. These copay assistence programs can come in form of upfront out-of-pocket financial support (e.g. Sun Pharmaceuticals for their Gleevec-alike imatinib mesylate) or the reduction of upfront cost to the patients (e.g. the cost of the […]
February 25, 2016 | By Tracy Staton in FiercePharma In an article in Science Translational Medicine, researchers from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute and the Broad Institute say patient loans could be designed to link payment to the clinical benefits of their treatment. In a way, they would be pay-for-performance deals–an idea […]
PharmaTimes on 17. November 2015 The National Institute for Health and Care Excellence has published final draft guidance rejecting the use of Kadcyla (trastuzumab-emtansine) for patients as the first and only targeted chemotherapy for secondary HER2-positive breast cancer, because of its high price tag – around £90,000 per course (list price). Full article at PharmaTimes: […]
18. Nov. 2015 in PharmaTimes The National Institute for Health and Care Excellence has turned down Amgen’s Repatha – the world’s first approved PCSK9 inhibitor – as an option for people with high cholesterol and mixed dyslipidaemia. Key reasons for the negative decision were: (1) no long-term outcomes data and thus, the question of whether […]
FiercePharma, 22. Apr. 2015 Japan’s health regulators are in the midst of deciding how to conduct cost-effective assessments for drugs and medical devices with under the Central Social Insurance Medical Council, better known as Chuikyo. The Government of Prime Minister Shinzo Abe adopted a plan last year that stipulates the trial rollout of cost-effective assessments […]
FierceHealthPayer, Feb 25, 2015 By Dina Overland Although almost 25 state programs employ higher copays for emergency department visits in an effort to decrease ED use, charging more when Medicaid recipients go to the ED may not be effective, reported Stateline. At least one multistate study determined that charging higher copays doesn’t necessarily lower ED […]